Status:
COMPLETED
Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) pati...
Eligibility Criteria
Inclusion
- First prescription of NOACs (rivaroxaban, dabigatran and apixaban) in the outpatient setting.
- Non valvular Atrial Fibrillation (NVAF) Patients
- aged ≥18 years
- at least one year of enrollment in the Audifarma database
- one year since first encounter with healthcare provider will be included in the study
Exclusion
- Patients with any record of index drug prescription prior to the enrolment period.
- Patients who qualify as members of more than one cohort study on the same day
Key Trial Info
Start Date :
February 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2018
Estimated Enrollment :
10528 Patients enrolled
Trial Details
Trial ID
NCT03474757
Start Date
February 28 2018
End Date
July 30 2018
Last Update
October 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Colombia